The patient that we studied had MIS-C on the basis of diagnostic criteria. He had fever and high inflammatory markers, including LDH, Ferritin, ESR, CRP, and organ involvement, including CNS, Skin, kidney, and Heart. He also had positive serologic markers (
6). The patient was initially admitted with the possibility of appendicitis and had visceral involvement with exudative ascites. Our patient underwent surgery, but he had no appendicitis or intra-abdominal surgery problems. In a study in Italy in 2021, among 1,010 children with MIS-C, 4.2% had an acute abdominal diagnosis, and 3.8% had surgery, of which 89.7% had a final diagnosis of appendicitis (
7). Creatinine increased, which was improved with supportive therapies such as CRRT. The prevalence of acute kidney injury (AKI) in COVID-19 patients is approximately 27.8%. Continuous renal replacement therapy (CRRT) is an important therapeutic modality in patients with COVID-19 and AKI. Absolute indications for initiating CRRT are overt uremia and hyperkalemia, but the optimal timing of therapy is the subject of debate (
8). A 15-year-old girl with renal failure and MIS-C was hospitalized in the United States and completely recovered. Moreover, BUN and creatinine increased but CRRT deferred in the setting of dehydration and intravenous therapy resulted in significant improvement. She also had skin rash and had antibodies to COVID-19 similar to our patient (
9). The optimum time for CRRT is 16.5 hr of AKI and mortality is lower than the interval of 28, 60, and 90 hr (
10). In our patient, early initiation of CRRT could prevent the progression of renal involvement and increase the patient's chances of survival. In a multisystem study in Europe, 286 children from 55 centers were included. The most common cardiovascular involvements were pericardial effusion, arrhythmias, coronary artery problems, and reduced left ventricular EF, which occurred in one-half of patients (
11). Our patient had decreased cardiac EF, and cardiotonic drugs were used for his treatment without significant improvement. There was a dramatic response to levosimendan. This drug is indicated in the short-term treatment of heart failure with inadequate effect of conventional therapy. Levosimendan opens sarcolemmal and mitochondrial potassium-ATP channels. It improves cardiac function with no increase in oxygen consumption. The effect is not attenuated by concomitant use of beta-blockers (
12). Our patient did not respond to epinephrine, norepinephrine, and milrinone, and dobutamine. The last drug, levosimendan, was effective, and the patient was treated successfully. Levosimendan is a vasodilator alongside the effect of inotrope. Its consumption is spreading in children (
13). Its use has not been reported in MIS-C patients. Our case experienced left side hemiparesis during the course of admission, and the cause was reported as an ischemic problem in the right temporoparietal zone of the cerebral cortex. In a case series report from Chile 2021, the neurologic complications were epilepsy exacerbation, anosmia, ageusia, headache, Guillain-Barre syndrome, encephalopathy, and demyelinating events (
14). A case of stroke firstly resulted in brain infarction and death in a child with COVID-19 (
15). The pathophysiology of acute cerebral ischemia in COVID-19 are para-infectious and immune-mediated, and hypercoagulable state and endothelial indentation (
15). The virus interferes with the function of ACE2 in cerebrovascular self-regulation, while reports of thrombosis, especially in the higher ages, have been reported (
16). Our patient developed cortical ischemia due to the involvement of the MCA artery. Fortunately, the paralysis of the left side of the body was improved during hospitalization and left no permanent complication. In our patient, despite a complete immunological examination, no clear immunodeficiency was detected. Cases of associated immunodeficiency are less common in patients with MIS-C (
17). All rheumatologic tests in our patient were negative except for anti-smith antibody. This antibody has high specificity for SLE. It is elevated in 30% of SLE and 8% of mixed connective tissue disease (MCTD) cases. Smith antigens are part of extractable nuclear antigens (
18). We found no correlation between MIS-C and SLE in the review of literature, and our patient did not show any symptoms of SLE. The anti-smith specificity of SLE antibodies decreases with the observation of positive cases in lung cancer (
19). Our patient was an MIS-C case that his vital organs of the brain, heart, and kidney were involved, that all were improved with the treatment. He had no problems at subsequent visits, and his tests were scheduled to be checked regularly.